Carib Scope

分类： health

  • Trinidad and Tobago Newsday – Saturday January 31st 2026

    Trinidad and Tobago Newsday – Saturday January 31st 2026

    The global dietary supplement industry, a multi-billion dollar market, operates in a regulatory gray zone that continues to challenge consumers and health professionals alike. Unlike pharmaceutical drugs that undergo rigorous FDA testing for safety and efficacy before market entry, supplements benefit from considerably more lenient regulations under the Dietary Supplement Health and Education Act (DSHEA) of 1994.

    This regulatory framework places the burden of proof on the FDA to demonstrate a supplement is unsafe after it has already reached consumers, rather than requiring pre-market approval. This fundamental difference means new supplement products can appear on store shelves and e-commerce platforms with minimal oversight, relying primarily on manufacturer integrity for quality and accuracy in labeling.

    Recent analyses reveal concerning gaps between marketing claims and scientific evidence. While some supplements demonstrate clear benefits for specific nutrient deficiencies or health conditions, many products make ambitious claims that lack robust clinical validation. The industry faces ongoing challenges with product contamination, inconsistent dosing, and occasionally, the inclusion of undeclared pharmaceutical ingredients in products marketed as ‘all-natural’.
    Health experts emphasize the importance of consulting healthcare providers before beginning any supplement regimen, particularly for individuals with pre-existing conditions or those taking prescription medications. Potential interactions between supplements and medications can produce unintended consequences that consumers may not anticipate.

    The digital age has further complicated the landscape, with social media influencers and targeted advertising creating unprecedented demand for various supplements often without adequate context about their appropriate use or limitations. Regulatory bodies worldwide are increasingly examining how to modernize oversight approaches for these products that occupy the complex intersection between food, medicine, and consumer wellness.

  • Holness opens $140m parent overnight suite at Bustamante Hospital

    Holness opens $140m parent overnight suite at Bustamante Hospital

    KINGSTON, Jamaica — A landmark healthcare facility designed to revolutionize family-centered pediatric care officially commenced operations at the Bustamante Hospital for Children following its inauguration by Prime Minister Andrew Holness on Friday.

    The newly constructed 36-bed parent overnight suite, developed through a collaborative partnership between the National Housing Trust (NHT), National Health Fund (NHF), and South East Regional Health Authority (SERHA), represents a significant advancement in Jamaica’s healthcare infrastructure. With an investment exceeding $140 million, the facility addresses the critical need for comfortable accommodation enabling parents and guardians to remain proximate to hospitalized children throughout their treatment journey.

    While prioritizing service to families traveling from overseas or distant Jamaican parishes, the suite extends comprehensive amenities to all visiting relatives. The modern complex features thoughtfully designed restrooms, a functional kitchenette, comfortable lounge areas, and private spaces dedicated to breastfeeding. Administrative functionality is ensured through incorporated office space for facility management and a conference room facilitating medical consultations between healthcare professionals and families.

    Prime Minister Holness articulated the philosophical underpinnings of the project during the opening ceremony, emphasizing: “Parents are not visitors in their child’s recovery; they are partners in it. They represent the familiar voice in an unfamiliar environment, the reassuring presence during moments of fear, and the steadying influence that promotes emotional security. Sometimes they constitute the medicine that transcends pharmaceutical prescription.”

    The initiative addresses the deterioration of previous facilities that no longer provided adequate restorative environments for families. As Bustamante Hospital has expanded its medical capabilities and patient volume over decades, the demand for modernized family support infrastructure became increasingly pressing.

    Health Minister Dr. Christopher Tufton characterized the development as both “long anticipated and urgently required,” noting the hospital’s unique status as the Caribbean’s premier pediatric institution serving children up to age twelve. He emphasized that maintaining modernization parallels the hospital’s clinical excellence, describing the suite as “another critical milestone achievement” in Jamaica’s healthcare evolution.

    Operational management and maintenance responsibilities for the new facility will be administered by SERHA, ensuring sustained quality service delivery for families navigating children’s healthcare challenges.

  • QEH performs Barbados’ first TAVI procedure

    QEH performs Barbados’ first TAVI procedure

    Barbados’ Queen Elizabeth Hospital (QEH) has achieved a transformative milestone in cardiac care with the successful execution of the nation’s inaugural Transcatheter Aortic Valve Implantation (TAVI) within its public healthcare system. This minimally invasive procedure, performed in the Cardiac Suite at the Lion’s Eye Care Centre, marks a significant leap forward in treating aortic stenosis—a dangerous narrowing of the heart valve predominantly affecting elderly patients who are often unsuitable for traditional open-heart surgery due to age and co-morbidities.

    A multidisciplinary team of specialists, led by Cardiothoracic Surgeon Dr. Christita Powlett and supported by Consultant Cardiologist Dr. Jose Lugo, Head of Cardiology Dr. Dawn Scantlebury, and Anesthesiologist Dr. Sherry Lashley, pioneered the procedure. The TAVI technique involves threading a catheter typically through the groin or a minor chest incision to deploy a new valve over the malfunctioning one. With an international success rate exceeding 98%, the procedure offers rapid symptom relief and dramatically reduced recovery periods, frequently enabling discharge within 72 hours.

    This achievement is particularly notable as it brings a advanced treatment modality previously available only in private sectors regionally—such as in Jamaica, Trinidad and Tobago, and Guyana—into the public health domain. To date, QEH has successfully completed two TAVI procedures despite significant infrastructural challenges. The hospital is currently operating with reduced theater capacity due to issues with the central air-conditioning system affecting six operating rooms.

    In response, hospital CEO Neil Clark and medical teams have implemented an innovative extended rotating theater schedule, utilizing three functional theaters for prolonged hours throughout weekdays and weekends. This contingency measure has enabled the continuation of urgent surgeries, addressed critical demand, and begun reducing the procedural backlog.

    While repairs are ongoing, QEH has procured a new air-conditioning unit scheduled for installation in March, which will serve as the permanent solution to restore full operational capacity. The hospital administration has extended apologies to patients experiencing delays and reaffirmed its commitment to advancing specialized medical services while ensuring safe, effective, and timely care for all Barbadians.

  • Grieving Mother Demands Answers After Baby Dies at KHMH

    Grieving Mother Demands Answers After Baby Dies at KHMH

    A third tragic infant mortality has emerged from Belize’s Karl Heusner Memorial Hospital (KHMH), prompting serious concerns about neonatal care standards. Alicia Kuylen, a grieving mother, has publicly detailed the catastrophic final hours of her two-month-old son Damani, who passed away under distressing circumstances in the hospital’s Neonatal Intensive Care Unit earlier this January.

    According to Kuylen’s account, the tragedy began when she brought her infant to KHMH on January 8th following a referral from a public clinic after the child stopped feeding. What followed was an agonizing multi-hour wait without medical attention, despite the visibly distressed infant’s condition. Kuylen reports that only after other mothers in the facility demanded intervention did medical staff finally attend to her son.

    The treatment provided included a blood transfusion using donation material that was nearly a month old—29 days according to hospital staff. When Kuylen expressed concern about the safety of using blood of this age for her infant, she was assured that medical professionals had consulted and would administer injections to prevent adverse reactions to the transfusion.

    Kuylen maintained a heartbreaking vigil throughout the procedure, documenting portions on video. She describes witnessing her son become unresponsive following the transfusion and multiple injections, including five sedatives. Despite attempts at resuscitation, the infant ceased breathing and died.

    This case represents the third infant death reported from KHMH within a single week, all occurring during the same time period. Minister of Health and Wellness Kevin Bernard has acknowledged the situation and states he is investigating the matter. Neither hospital officials nor the Ministry of Health have provided formal comments despite repeated requests from news organizations.

  • De kleine vervelende vlieg ‘uit Egypte’ bijt weer

    De kleine vervelende vlieg ‘uit Egypte’ bijt weer

    Suriname’s Ministry of Health has activated emergency alerts as chikungunya infections demonstrate a concerning upward trajectory across the nation. Public Works waste management services have intensified efforts to collect bulk refuse from public areas, marking the opening of another seasonal offensive against a persistent adversary: the Aedes aegypti mosquito.

    This insect, whose scientific nomenclature translates to ‘unpleasant from Egypt,’ represents far more than a mere nuisance. While serving as a food source for certain bird and amphibian species, its primary human impact involves transmitting devastating viral diseases including yellow fever, dengue, chikungunya, and Zika. Historical eradication attempts—notably Brazil’s 1958 declaration of being Aedes-free through DDT deployment—ultimately failed due to insecticide resistance, environmental concerns, and cross-border reinfestation.

    The female Aedes aegypti requires protein-rich blood meals for egg production, leading to aggressive daytime biting behavior within remarkably limited flight ranges of 50-800 meters. This localized movement pattern means neighborhood sanitation directly determines community vulnerability. Even minor water accumulation in bottle caps or blocked gutters can become breeding grounds, making collective participation in elimination efforts essential.

    Dengue (characterized by high fever and ocular pain), chikungunya (causing severe arthralgia), and Zika (associated with birth defects) share overlapping symptomatology including fever, chills, and profound lethargy. Definitive diagnosis requires blood testing, though treatment primarily involves supportive care with hydration, rest, and analgesics. Hospitalization becomes necessary when warning signs like hemorrhage, persistent vomiting, or neurological complications emerge.

    Ultimately, Aedes-borne diseases thrive through environmental neglect. Structural waste accumulation, stagnant water reservoirs, and inadequate public maintenance create ideal vector habitats. Both governmental action and individual responsibility—particularly in maintaining clean residential perimeters—prove critical in breaking disease transmission cycles. The biting truth remains: mosquito proliferation directly reflects communal sanitation standards.

  • BOG: Aanpak chikungunya staat of valt met inzet burgers

    BOG: Aanpak chikungunya staat of valt met inzet burgers

    Suriname has reported its first confirmed cases of chikungunya virus in nearly ten years, prompting urgent public health measures and calls for coordinated action between government and citizens. The Bureau for Public Health (BOG) confirmed the outbreak in January 2026, with epidemiological evidence suggesting initial infections may have occurred as early as December 2025.

    Acting Head of Environmental Inspection at BOG, Stephanie Cheuk A Lam, revealed that the outbreak follows a predictable pattern, with an expected peak period of three to four months before gradual decline. Given the timeline of initial infections, health authorities anticipate seeing reduced transmission within coming months.

    The resurgence appears to have been imported from outside Suriname before establishing local transmission through Aedes mosquitoes. Confirmed cases are concentrated in Paramaribo’s northern districts, city center, and Kwatta area, with additional infections reported in Wanica, Commewijne, and Marowijne (Moengo).

    In response to the outbreak, multiple BOG departments have mobilized in collaboration with Public Works. Current efforts include removal of bulk waste in high-risk areas, household inspections by environmental officers, larval control operations, and entomological studies on mosquito density.

    Cheuk A Lam emphasized that source reduction remains critical: ‘Spraying alone is insufficient. Eliminating stagnant water around residences is essential. Only through collective effort can we effectively contain chikungunya’s spread.’

    Suriname’s centralized laboratory conducts routine testing for multiple arboviruses including dengue, yellow fever, oropouche, and mayaro, enabling health authorities to confirm no chikungunya infections have been detected in the country over the past decade. Beyond laboratory-confirmed cases, BOG is also monitoring suspected cases and one probable case.

    With no specific medication or vaccine available, treatment focuses solely on symptom management, making prevention and containment the primary defense against further spread.

  • Suriname records nearly 150 cases of chikungunya virus cases

    Suriname records nearly 150 cases of chikungunya virus cases

    Suriname’s Health Minister André Misiekaba has issued an urgent public health alert following the confirmation of the nation’s first chikungunya-related fatality and 134 laboratory-confirmed cases of the mosquito-borne virus. Addressing the National Assembly, Minister Misiekaba revealed the epidemiological profile of the outbreak, with confirmed infections spanning ages from 11 months to 85 years. The most affected demographic groups are adults aged 25-44 (27 cases) and 45-64 (38 cases).

    The deceased individual, who had serious underlying health conditions, is currently under investigation by the Public Health Bureau (BOG). The outbreak has been confirmed in three regions including the capital city of Paramaribo, prompting immediate government action.

    Minister Misiekaba emphasized the severity of the situation by noting that internationally, one confirmed death typically indicates at least a thousand actual infections in the community. ‘I’m not saying this to cause panic but to call on society to be vigilant, because Suriname is dealing with a serious outbreak,’ the Minister stated during his address.

    A multidisciplinary task force comprising experts from the Health Ministry, BOG, Medical Mission, and Regional Health Service has been mobilized to implement comprehensive communication strategies and community engagement initiatives.

    The Health Ministry identified high-risk groups including seniors, young children, chronically ill individuals (particularly those with diabetes and heart conditions), and pregnant women in their final trimester.

    Current containment efforts focus on eliminating mosquito breeding grounds in the most affected areas, with plans to expand these operations progressively. Insecticide spraying operations are pending as necessary supplies remain in transit.

    Health authorities have issued specific preventive guidelines urging citizens to eliminate stagnant water sources, cover water storage containers, apply mosquito repellent, wear protective clothing, and use mosquito nets while sleeping.

    Stephanie Cheuk A Lam, Acting Head of the Environmental Inspectorate at BOG, projected the outbreak peak could persist for three to four months, emphasizing that ‘Without the commitment of every citizen, we remain vulnerable.’ Minister Misiekaba reinforced this message, stating unequivocally that ‘The government cannot do this alone. Society must help to control this outbreak.’

  • Chikungunya-uitbraak: 134 bevestigde besmettingen, één overlijden gemeld

    Chikungunya-uitbraak: 134 bevestigde besmettingen, één overlijden gemeld

    Suriname’s Health Minister André Misiekaba has delivered an urgent address to the National Assembly regarding the escalating chikungunya outbreak, confirming 134 laboratory-verified infections across a broad demographic spectrum from 11-month-old infants to 85-year-old seniors. The ministry reported one fatality currently under investigation by the Bureau of Public Health (BOG), involving a patient with significant pre-existing medical conditions.

    A multidisciplinary task force led by Maureen van Dijk is coordinating response efforts with support from health ministry experts, BOG, Medical Mission, and Regional Health Service. Dr. Hedwig Goede has been appointed to manage risk communication and community engagement strategies.

    Infection clusters have been identified in three districts: Paramaribo, Commewijne, and most recently Nickerie. Minister Misiekaba highlighted that international health metrics suggest approximately 1,000 unreported infections may exist for each confirmed death, though he clarified this assessment aims to promote vigilance rather than incite panic.

    High-risk populations include elderly citizens, young children, chronically ill individuals (particularly those with diabetes or heart conditions), and late-term pregnant women. Current treatment protocols emphasize acetaminophen for pain and fever management, coupled with rest, proper nutrition, and hydration. Chronically ill patients experiencing persistent symptoms beyond 7-10 days are advised to seek immediate medical attention.

    Government initiatives include targeted elimination of mosquito breeding sites in high-transmission zones, with expansion planned progressively. Collaborative efforts with district commissioners in Nickerie focus on waste collection and public greenery maintenance. Insecticide spraying operations await delivery of necessary supplies, after which aerial and ground deployments will commence.

    All district commissioners have received operational briefings, while PAHO/WHO channels are disseminating clinical guidance to healthcare providers. Minister Misiekaba emphasized collective responsibility: “Government cannot solve this alone. Society must contribute to bringing this outbreak under control” through eliminating stagnant water, covering water containers, using mosquito repellent, wearing protective clothing, and sleeping under nets.

  • Confirmed arboviral cases decline in Cuba

    Confirmed arboviral cases decline in Cuba

    Cuban health authorities have announced a significant nationwide reduction in dengue fever cases, with sustained vector control operations confirmed through guaranteed funding. The update was delivered by Deputy Minister of Public Health Carilda Peña during a high-level meeting chaired by President Miguel Diaz-Canel, which convened experts and scientists to address critical health challenges.

    Epidemiological analysis presented at the meeting revealed a consistent downward trend in infections across all regions. Mathematician Raul Guinovart Diaz, Director of Science and Technology at the University of Havana, provided detailed metrics showing particularly substantial declines in western and central provinces. While the eastern region demonstrates a more moderate decrease, it continues to follow the same positive trajectory.

    Dr. Peña Garcia confirmed complete financial backing for the comprehensive vector control initiative through the first half of the year. This funding ensures the uninterrupted implementation of scheduled larvicide application cycles, a cornerstone of Cuba’s mosquito eradication strategy. Additionally, health officials are actively procuring necessary supplies to maintain campaign operations through the latter half of the year, preventing any disruption in preventive measures.

    The coordinated response highlights Cuba’s integrated approach to disease management, combining scientific expertise with guaranteed resource allocation to combat mosquito-borne illnesses effectively.

  • Cuba on the path to biosimilar drugs

    Cuba on the path to biosimilar drugs

    Cuba’s state-owned biotechnology conglomerate BioCubaFarma is implementing a strategic expansion of its biosimilar pharmaceuticals portfolio to enhance medical treatment accessibility within the National Health System while simultaneously boosting export capabilities. This initiative received presidential attention during Miguel Diaz-Canel’s regular consultation with scientific experts addressing national healthcare priorities.

    Biosimilar medications, which undergo rigorous regulatory approval processes, demonstrate equivalent molecular structure, biological activity, safety profiles, and therapeutic efficacy to their reference biologic products. These pharmaceuticals contain identical active ingredients to original biologics but become available at significantly reduced costs due to abbreviated development pathways.

    The BioCubaFarma group, Cuba’s premier developer of pharmaceutical products and medical technologies, currently markets multiple biosimilar and generic medications. Their portfolio includes EPOCIM for managing chronic kidney failure and Leukocim for oncological applications. Additional offerings comprise Heberon Alfa R (Interferon alpha 2B) and its pegylated formulation PEG-Heberon, both exhibiting anti-infective and anticancer properties; human albumin for treating hypoproteinemia and nephrotic syndrome; and the anticoagulant Enoxaparin sodium.

    This strategic pharmaceutical development serves dual objectives: facilitating introduction of novel treatments into Cuba’s healthcare infrastructure while expanding the corporation’s export catalog. The initiative further aims to diversify therapeutic options by incorporating medications not presently available in the Cuban market, thereby complementing existing research and development pipelines.

    The comprehensive approach demonstrates Cuba’s commitment to advancing biomedical innovation while addressing healthcare economic challenges through scientifically validated alternatives to expensive biologic therapies.